# Tecarfarin Anti-Coagulation Trial (TACT)

> **NCT02522221** · PHASE3 · UNKNOWN · sponsor: **Espero Biopharma** · enrollment: 1000 (estimated)

## Conditions studied

- Thromboembolism
- Thrombosis

## Interventions

- **DRUG:** Warfarin
- **DRUG:** tecarfarin

## Key facts

- **NCT ID:** NCT02522221
- **Lead sponsor:** Espero Biopharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-01
- **Primary completion:** 2019-03-30
- **Final completion:** 2019-07-01
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2018-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02522221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02522221, "Tecarfarin Anti-Coagulation Trial (TACT)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02522221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*